JP2022547061A - 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法 - Google Patents

進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法 Download PDF

Info

Publication number
JP2022547061A
JP2022547061A JP2022514608A JP2022514608A JP2022547061A JP 2022547061 A JP2022547061 A JP 2022547061A JP 2022514608 A JP2022514608 A JP 2022514608A JP 2022514608 A JP2022514608 A JP 2022514608A JP 2022547061 A JP2022547061 A JP 2022547061A
Authority
JP
Japan
Prior art keywords
antibody
human anti
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022514608A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021043955A5 (https=
JP2022547061A5 (https=
Inventor
ジアン，ハイイー
フアン，イーファン
デニス，フィリップ
シャイア，ノラ
アームストロング，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2022547061A publication Critical patent/JP2022547061A/ja
Publication of JPWO2021043955A5 publication Critical patent/JPWO2021043955A5/ja
Publication of JP2022547061A5 publication Critical patent/JP2022547061A5/ja
Priority to JP2025097923A priority Critical patent/JP2025148350A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022514608A 2019-09-05 2020-09-04 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法 Pending JP2022547061A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025097923A JP2025148350A (ja) 2019-09-05 2025-06-11 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962896224P 2019-09-05 2019-09-05
US62/896,224 2019-09-05
PCT/EP2020/074714 WO2021043955A1 (en) 2019-09-05 2020-09-04 Compositions and methods for treating extensive stage small cell lung cancer (es-sclc)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025097923A Division JP2025148350A (ja) 2019-09-05 2025-06-11 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022547061A true JP2022547061A (ja) 2022-11-10
JPWO2021043955A5 JPWO2021043955A5 (https=) 2023-09-11
JP2022547061A5 JP2022547061A5 (https=) 2023-09-11

Family

ID=72521575

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022514608A Pending JP2022547061A (ja) 2019-09-05 2020-09-04 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法
JP2025097923A Pending JP2025148350A (ja) 2019-09-05 2025-06-11 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025097923A Pending JP2025148350A (ja) 2019-09-05 2025-06-11 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法

Country Status (10)

Country Link
US (2) US12012453B2 (https=)
EP (1) EP4025249A1 (https=)
JP (2) JP2022547061A (https=)
KR (1) KR20220058601A (https=)
CN (1) CN114340673A (https=)
AU (2) AU2020342713A1 (https=)
CA (1) CA3151838A1 (https=)
IL (1) IL290834A (https=)
TW (1) TWI907357B (https=)
WO (1) WO2021043955A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119255817A (zh) * 2022-03-28 2025-01-03 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
TW202602492A (zh) * 2024-04-05 2026-01-16 瑞典商阿斯特捷利康公司 局限期小細胞肺癌之治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018178040A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
EP3277318A1 (en) * 2015-04-01 2018-02-07 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
ES2980794T3 (es) * 2015-09-15 2024-10-03 Acerta Pharma Bv Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK
AR108468A1 (es) * 2016-05-13 2018-08-22 Medimmune Llc POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
CN112585166A (zh) * 2018-06-23 2021-03-30 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂、铂剂和拓扑异构酶ii抑制剂治疗肺癌的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018178040A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"CT03043872 Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated E", CLINICALTRIALS.GOV, JPN6024033971, 6 June 2019 (2019-06-06), ISSN: 0005692006 *
"アストラゼネカのイミフィンジ、第III相CASPIAN試験の中間解析において、進展型小細胞肺がんの一次治療薬と", アストラゼネカ, JPN6024033968, 5 July 2019 (2019-07-05), ISSN: 0005692004 *
CLIN. TRANSL. ONCOL., vol. vol.21, issue 8, JPN6024033969, January 2019 (2019-01-01), pages 961 - 976, ISSN: 0005692005 *
N. ENGL. J. MED., vol. vol.379, issue 23, JPN6024033967, 2018, pages 2220 - 2229, ISSN: 0005692003 *

Also Published As

Publication number Publication date
KR20220058601A (ko) 2022-05-09
US20240376206A1 (en) 2024-11-14
IL290834A (en) 2022-04-01
EP4025249A1 (en) 2022-07-13
US20210070863A1 (en) 2021-03-11
AU2020342713A1 (en) 2022-04-14
AU2025202735A1 (en) 2025-05-08
TW202124440A (zh) 2021-07-01
US12012453B2 (en) 2024-06-18
TWI907357B (zh) 2025-12-11
JP2025148350A (ja) 2025-10-07
WO2021043955A1 (en) 2021-03-11
CN114340673A (zh) 2022-04-12
CA3151838A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
JP7721494B2 (ja) 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用
CN106573977B (zh) 针对ceacam1的人源化抗体
JP2025148350A (ja) 進展型小細胞肺癌（ｅｓ－ｓｃｌｃ）の治療のための組成物及び方法
JP2024038034A (ja) 膀胱癌の抗ｐｄ－ｌ１抗体治療
CN112351794A (zh) 用于尿路上皮癌的免疫治疗方法
KR20230093282A (ko) 폐암에 대한 lag-3 길항제 요법
CA3251366A1 (en) POLYTHERAPY AGAINST COLORECTAL CARCINOMA
TW202143993A (zh) 抗tnfr2抗體及其用途
KR20240099362A (ko) 혈액암에 대한 lag-3 길항제 요법
US20220073622A1 (en) Compositions and Methods for Treating Late Stage Lung Cancer
CN110944663A (zh) 用于治疗非小细胞肺癌的抗pd-l1和抗ctla-4抗体
EA050488B1 (ru) Композиции и способы для лечения рака легкого на поздней стадии
JP2023103254A (ja) 後期肺癌の処置のための組成物及び方法
CN113272331A (zh) 用于治疗癌症的tim-3抗体以及与其他检查点抑制剂的组合
EP4205763A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
CN118829446A (zh) 使用ctla-4和pd-1双特异性抗体的治疗方法
HK40117614A (zh) 使用ctla-4和pd-1双特异性抗体的治疗方法
EA050629B1 (ru) Композиции и способы для лечения рака легкого на поздней стадии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250611